Tag «american diabetes association gestational diabetes»

ViaCyte Receives More Funding for Diabetes Stem Cell Therapy | GEN News Highlights | GEN

The Montreal Heart Institute (MHI) agreed to collaborate with AstraZeneca to search the genomes of up to 80,000 patients for genes associated with cardiovascular diseases and diabetes, their complications, and treatment outcomes. However, intriguing new evidence shows that hUC-MSCs isolated from women with gestational diabetes demonstrate premature aging, poorer cell growth, and altered metabolic function, as reported in an article in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. This study aims to identify the possible association of I/D variants of the ACE gene and M268T (rs699) of the AGT gene of renin-angiotensin-aldosterone system (RAAS). Frankly, it’s hard to over-estimate their contribution to science. The author provides his perspectives on the large knowledge base of published studies that have assessed the safety and effectiveness of different diabetes therapeutic approaches on glycemic control and hypoglycemic

Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus. – PubMed

To assess the current status of glycemic control in patients with type 2 diabetes treated with a combination of metformin and sulfonylurea for >3 months, as measured by glycosylated hemoglobin (HbA1c). The five-dimension EuroQol questionnaire (EQ-5D), SHIELD Weight Questionnaire-9 (WQ-9), Impact of Weight on Quality of Life-Lite (IWQOL-Lite) questionnaire and the Diabetes Treatment Satisfaction Questionnaire (DTSQ) were used to evaluate health status and health-related quality of life (HRQoL) at baseline and week 52. Costs were evaluated from the German SHI perspective based on official 2005 prices. The principal providers were family practitioners, general internists, cardiologists, or endocrinologists. Of them, 18 patients complicated by paraplegia, and 25 patients had more than one of concomitant diseases. A numerically greater proportion of the dapagliflozin group reported improvement in all nine SHIELD WQ-9 items compared with placebo, and the difference was statistically